Clinical Trial Update: Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing aqueous concentrations and PGE2 inhibition between ketorolac 0.4% and bromfenac 0.09% in cataract patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract

Drugs mentioned

• Bromfenac ophthalmic solution 0.09% (bromfenac)
• ketorolac ophthalmic solution 0.4% (ketorolac tromethamine)

Snippet

Sponsor: Innovative Medical | Conditions: Cataract | Phase 4 | Status: COMPLETED